

IN THE CLAIMS:

Please add for consideration new claim numbers 40-45.

Claims 1-21 (Canceled)

22. (Withdrawn) A pharmaceutical composition comprising a molecule targeted to a tissue selected from the group consisting of pulmonary circulation, intestinal circulation, pulmonary airways, lumen of the small intestine, dendritic cells in the skin and T cell areas of lymphoid organs, thymus, and brain, which molecule is conjugated to a DEC-ligand, which DEC-ligand is selected from the group consisting of a carbohydrate that binds DEC and an anti-DEC antibody, and a pharmaceutically acceptable carrier.

23. (Withdrawn) The pharmaceutical composition of claim 22, wherein the molecule is selected from the group consisting of an anti-cancer drug, an anti-viral drug, an antibiotic, an anti-parasitic drug, and an anti-inflammatory drug.

Claims 24-25 (Canceled)

26. (Previously presented) A vaccine for inducing an immune response comprising an antigen conjugated to an anti-human Dendritic and Epithelial Cell 205 (DEC-205) antibody or an anti-murine DEC-205 antibody reactive with a human DEC-205 protein, said human DEC-205 protein comprising an amino acid sequence as set forth in SEQ ID 1.

27. (Previously presented) The vaccine of claim 26, wherein the antigen is selected from the group consisting of a virus, a bacterium, a parasite, and a tumor.

28. (Original) The vaccine of claim 26, wherein the immune stimulator is selected from the group consisting of a cytokine, a lymphokine, and an adjuvant.

29. (Withdrawn) A composition to induce immune suppression comprising an autoantigen or an allergen conjugated to a DEC-ligand, wherein the DEC ligand is selected from the group consisting of a carbohydrate that binds DEC and an anti-DEC antibody, with the proviso that the composition lack immune stimulatory agents.

30. (Withdrawn) The composition of claim 29, wherein the autoantigen is selected from the group consisting of myelin basic protein, collagen or a fragment thereof, DNA, a nuclear protein, a nucleolar protein, a mitochondrial protein, and a pancreatic  $\beta$ -cell protein.

Claims 31-34 (Canceled)

35. (previously presented) A vaccine for inducing an immune response comprising an antigen conjugated to an anti-human Dendritic and Epithelial Cell 205 (DEC-205) antibody, wherein the antibody is reactive with the amino acid sequence as set forth in SEQ ID NO: 1.

36. (previously presented) A vaccine for inducing an immune response comprising an antigen conjugated to an anti-mouse Dendritic and Epithelial Cell-205 (DEC-205) antibody, wherein the antibody is reactive with the amino acid sequence as set forth in SEQ ID NO: 1.

37. (previously presented) The vaccine of any one of claims 26, 35, or 36, further comprising an immune stimulator.

38. (previously presented) The vaccine of claim 37, wherein the immune stimulator is selected from the group consisting of a cytokine, a lymphokine, and an adjuvant.

39. (previously presented) The vaccine of any one of claims 26, 35, or 36, wherein the antigen is selected from the group consisting of a virus, a bacterium, a parasite, and a tumor.

40. (new) A vaccine for inducing an immune response comprising an antigen conjugated to an antibody which binds mouse Dendritic and Epithelial Cell 205 (DEC-205) having the amino acid sequence of SEQ ID NO:3, wherein the antibody cross reacts with human DEC-205.

41. (new) The vaccine of claim 40, further comprising an immune stimulator.

42. (new) The vaccine of claim 41, wherein the immune stimulator is selected from the group consisting of a cytokine, a lymphokine, and an adjuvant.

43. (new) The vaccine of claim 40, wherein the antigen is selected from the group consisting of a virus, a bacterium, a parasite, and a tumor antigen.

44. (new) The method of claim 40, wherein the antigen is bound to the antibody to DEC-205 by means of a cross-linking agent.

45. (new) The method of claim 40, wherein a light chain or a heavy chain of the antibody to DEC-205, and the antigen, are present on a single polypeptide chain.